Literature DB >> 17452226

Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools.

Robert J Klaassen1, Victor S Blanchette, Dorothy Barnard, Cindy D Wakefield, Christine Curtis, Catharine S Bradley, Ellis J Neufeld, George R Buchanan, Mariana P Silva, Anthony K C Chan, Nancy L Young.   

Abstract

OBJECTIVE: To refine the disease-specific health-related quality of life measure in immune (idiopathic) thrombocytopenic purpura (ITP) and to determine its validity, reliability, and responsiveness to change. STUDY
DESIGN: The initial phase involved cognitive debriefing of 12 families, on the basis of which the measure was modified and then named Kids' ITP Tools (KIT). The measure was administered on 2 occasions with the Pediatric Quality of Life Inventory (PedsQL) to 41 patients with acute ITP and 49 patients with chronic ITP, 2 to 18 years old, and their parents (proxy-respondents) at 6 North American centers.
RESULTS: Patients with acute ITP had lower scores when compared with patients with chronic ITP (child 64 versus 76, proxy 69 versus 77). The KIT moderately correlated with the PedsQL. Child versus proxy KIT scores showed moderate correlation, and the KIT was superior to the PedsQL. Test-retest reliability was substantial in the child report, but only moderate for the proxy report, similar to the PedsQL. The KIT showed a mean score change of 13 in the child and 15 in the proxy, which was greater than the PedsQL child's change of 7 and proxy change of 5.
CONCLUSION: The KIT is valid, with good distinction between acute and chronic ITP and a moderate correlation with the PedsQL. The KIT demonstrated reliability comparable with that of the PedsQL, yet it was more responsive to change. Therefore the KIT can be used as an outcome measure in future clinical trials of childhood ITP.

Entities:  

Mesh:

Year:  2007        PMID: 17452226     DOI: 10.1016/j.jpeds.2007.01.037

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  19 in total

Review 1.  Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.

Authors:  Lisa J Toltl; Donald M Arnold
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

2.  Health-related quality of life in children with newly diagnosed immune thrombocytopenia.

Authors:  Katja M J Heitink-Pollé; Lotte Haverman; Kim V Annink; Sarah J Schep; Masja de Haas; Marrie C A Bruin
Journal:  Haematologica       Date:  2014-06-20       Impact factor: 9.941

3.  Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.

Authors:  Rachael F Grace; Kristin A Shimano; Rukhmi Bhat; Cindy Neunert; James B Bussel; Robert J Klaassen; Michele P Lambert; Jennifer A Rothman; Vicky R Breakey; Kerry Hege; Carolyn M Bennett; Melissa J Rose; Kristina M Haley; George R Buchanan; Amy Geddis; Adonis Lorenzana; Michael Jeng; Yves D Pastore; Shelley E Crary; Michelle Neier; Ellis J Neufeld; Nolan Neu; Peter W Forbes; Jenny M Despotovic
Journal:  Am J Hematol       Date:  2019-04-29       Impact factor: 10.047

4.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

5.  The Pediatric Toronto Extremity Salvage Score (pTESS): Validation of a Self-reported Functional Outcomes Tool for Children with Extremity Tumors.

Authors:  Janine Piscione; Wendy Barden; Janie Barry; Alexandra Malkin; Trisha Roy; Tyki Sueyoshi; Karen Mazil; Steven Salomon; Firas Dandachli; Anthony Griffin; Hugo Saint-Yves; Pina Giuliano; Abha Gupta; Peter Ferguson; Katrin Scheinemann; Michelle Ghert; Robert E Turcotte; Lucie Lafay-Cousin; Joel Werier; Caron Strahlendorf; Marc Isler; Sophie Mottard; Samina Afzal; Megan E Anderson; Sevan Hopyan
Journal:  Clin Orthop Relat Res       Date:  2019-09       Impact factor: 4.176

6.  IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP.

Authors:  Manuel Carcao; Mariana Silva; Michele David; Robert J Klaassen; MacGregor Steele; Victoria Price; Cindy Wakefield; Lussia Kim; Derek Stephens; Victor S Blanchette
Journal:  Blood Adv       Date:  2020-04-14

7.  Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.

Authors:  Hannah Tamary; Jelena Roganovic; Meera Chitlur; Diane J Nugent
Journal:  Ann Hematol       Date:  2010-04-01       Impact factor: 3.673

8.  Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.

Authors:  Cindy E Neunert; George R Buchanan; Paul Imbach; Paula H B Bolton-Maggs; Carolyn M Bennett; Ellis J Neufeld; Sara K Vesely; Leah Adix; Victor S Blanchette; Thomas Kühne
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

Review 9.  Eltrombopag for use in children with immune thrombocytopenia.

Authors:  Taylor Olmsted Kim; Jenny Despotovic; Michele P Lambert
Journal:  Blood Adv       Date:  2018-02-27

10.  Measuring disease-specific quality of life in rare populations: a practical approach to cross-cultural translation.

Authors:  Victoria E Price; Robert J Klaassen; Paula H B Bolton-Maggs; John D Grainger; Christine Curtis; Cindy Wakefield; Gustavo Dufort; Arne Riedlinger; Christophe Soltner; Victor S Blanchette; Nancy L Young
Journal:  Health Qual Life Outcomes       Date:  2009-10-23       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.